Talha Badar, Hematologist-Oncologist at Mayo Clinic, shared on X:
“Menin inhibitors at ASH26: a growing footprint across R/R AML, frontline combinations, MRD-directed therapy and transplant strategies.
A meeting guide to ziftomenib, revumenib, enzomenib and bleximenib
Date: Saturday, December 12
Abstract 66
9:30 – 11 am / Great Hall AD
KOMET-008: ziftomenib + gilteritinib in R/R NPM1/FLT3-mutated AML. At ≥200 mg (n=41): ORR 68%, CRc 41%, CR/CRh 34%. Grade 3 differentiation syndrome 10% (n=48). Median follow-up only 4.6 months.
Abstract 388
4 – 5:30 pm / Great Hall AD
INTERCEPT: pre-emptive revumenib for MRD relapse. MRD clearance: 45% in NPM1m (9/20 evaluable), 75% in KMT2Ar (6/8). No differentiation syndrome. Small, nonrandomized cohorts; survival benefit remains unknown.
Date: Sunday, December 13
Abstract 661
4:30 – 6 pm / Hall B
cAMeLot-1: bleximenib phase 2 in R/R AML. CR/CRh 51.2% in KMT2Ar (n=43), 40.4% in NPM1m (n=57). Differentiation syndrome 28% and 11%, respectively. Durability remains early.
Abstract 662
Beat AML: frontline azacitidine/venetoclax/revumenib in NPM1m/KMT2Ar AML, age >60 (n=82). ORR 90%, CR 68%, median OS 24.3 months. Differentiation syndrome 16%. Single-arm evidence.
Abstract 663
Pivotal phase 2 enzomenib in R/R KMT2Ar acute leukemia (n=56). CR/CRh threshold met; detailed response results expected at the podium.
Abstract 715
4:30 – 6 pm / Great Hall AD
Revumenib post-allo-HCT maintenance, phase 1 (n=18). No relapse, nonrelapse mortality or grade 2–4 acute GVHD at median 5.1 months. An early feasibility signal, not established relapse prevention.
Abstract 3418
TriNetX: menin inhibitors vs ven/HMA in R/R NPM1m AML. Mortality HR 0.28 after propensity matching. Retrospective association, not proof of comparative benefit. Time/room unverified.
Date: Monday, December 14
Abstract 902
2:45 – 4:15 pm / Great Hall BC
KOMET-007: ziftomenib + 7+3 + quizartinib in newly diagnosed NPM1m/FLT3-ITD AML. CRc 100% at 200/400 mg (15 evaluable); local NPM1 MRD negativity 57% of CRc. Very small cohort, short follow-up.
Abstract 904
SAVE: all-oral revumenib + decitabine/cedazuridine + venetoclax in newly diagnosed unfit NPM1m/KMT2Ar AML (n=30). CRc 79%, flow-MRD negativity 91% of CRc, 1-year OS 67%. Differentiation syndrome 25%.
Abstract 905
AUGMENT-101: revumenib as a bridge to HCT (n=59 transplanted in remission). MRD negativity 86% among CRc; 12-month OS 68% in KMT2Ar and 90% in NPM1m. Selected analysis of patients who reached HCT.
6 – 8 pm / Hall F
Poster 5152
Enzomenib in R/R NPM1m acute leukemia. At 300 mg BID (n=30): ORR 57%, CR/CRh 43%; differentiation syndrome 8.9% overall.
Poster 5190
KOMET-001: ziftomenib in R/R NPM1wt/KMT2Ar-negative AML with MEIS1-associated lesions (n=64). CR 6%, MLFS 2%. Exploratory, hypothesis-generating. Time/room unverified.
The key questions: durability, MRD depth, differentiation syndrome and the incremental benefit of adding a menin inhibitor to existing backbones. Predominantly early-phase, single-arm data; avoid cross-trial comparisons. Abstract findings may change at presentation.”
You can also read:
Time Toxicity in Acute Myeloid Leukemia Care and the Potential of All-Oral Therapy
